NVNO (enVVeno Medical) Beginning Cash Position: $3.07 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVNO enVVeno Medical Corp NVNO
30 GF Score
Price $10.63
! 3 Warning Signs
View Full Analysis

What is enVVeno Medical Beginning Cash Position?

enVVeno Medical NVNO +2.17% 30 Beginning Cash Position is $3.07 Mil as of Mar. 2026. GuruFocus rates NVNO with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

enVVeno Medical's Beginning Cash Position for the quarter that ended in Mar. 2026 was $3.07 Mil.

enVVeno Medical's quarterly Beginning Cash Position increased from Sep. 2025 ($2.29 Mil) to Dec. 2025 ($2.33 Mil) and increased from Dec. 2025 ($2.33 Mil) to Mar. 2026 ($3.07 Mil).

enVVeno Medical's annual Beginning Cash Position declined from Dec. 2023 ($4.56 Mil) to Dec. 2024 ($3.62 Mil) and declined from Dec. 2024 ($3.62 Mil) to Dec. 2025 ($1.75 Mil).

enVVeno Medical Beginning Cash Position Related Terms

enVVeno Medical Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for enVVeno Medical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enVVeno Medical Beginning Cash Position Chart

enVVeno Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 54.73 4.56 3.62 1.75

enVVeno Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 2.94 2.29 2.33 3.07
NVNO
30GF Score
enVVeno Medical Corp NVNO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enVVeno Medical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $3.07 Mil mean?
enVVeno Medical (NVNO) has a Beginning Cash Position of $3.07 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on enVVeno Medical and its competitors.
Is enVVeno Medical's Beginning Cash Position too high?
enVVeno Medical's current Beginning Cash Position is $3.07 Mil. Overall, enVVeno Medical has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's Beginning Cash Position compare to CODX and HSCS?
enVVeno Medical's Beginning Cash Position of $3.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on enVVeno Medical and its competitors. enVVeno Medical's current Beginning Cash Position is $3.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current Beginning Cash Position of $3.07 Mil. The current Beginning Cash Position is $3.07 Mil. enVVeno Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current Beginning Cash Position is $3.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enVVeno Medical Business Description

Address 70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
30GF Score

Get the complete analysis for NVNO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.63
Price